These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Transcription factors as therapeutic targets in CNS disorders. Kane MJ; Citron BA Recent Pat CNS Drug Discov; 2009 Nov; 4(3):190-9. PubMed ID: 19891598 [TBL] [Abstract][Full Text] [Related]
6. DNA-binding small molecules as inhibitors of transcription factors. Leung CH; Chan DS; Ma VP; Ma DL Med Res Rev; 2013 Jul; 33(4):823-46. PubMed ID: 22549740 [TBL] [Abstract][Full Text] [Related]
8. Pax-8: Molecular biology, pathophysiology, and potential pathogenesis. Zhou Q; Li H; Cheng Y; Ma X; Tang S; Tang C Biofactors; 2024; 50(3):408-421. PubMed ID: 37988248 [TBL] [Abstract][Full Text] [Related]
9. Cancer network activity associated with therapeutic response and synergism. Serra-Musach J; Mateo F; Capdevila-Busquets E; de Garibay GR; Zhang X; Guha R; Thomas CJ; Grueso J; Villanueva A; Jaeger S; Heyn H; Vizoso M; Pérez H; Cordero A; Gonzalez-Suarez E; Esteller M; Moreno-Bueno G; Tjärnberg A; Lázaro C; Serra V; Arribas J; Benson M; Gustafsson M; Ferrer M; Aloy P; Pujana MÀ Genome Med; 2016 Aug; 8(1):88. PubMed ID: 27553366 [TBL] [Abstract][Full Text] [Related]
10. New drugs target hypoxia response in tumors. Garber K J Natl Cancer Inst; 2005 Aug; 97(15):1112-4. PubMed ID: 16077066 [No Abstract] [Full Text] [Related]
11. Targeting inflammation-induced transcription factor activation: an open frontier for glioma therapy. Sen E Drug Discov Today; 2011 Dec; 16(23-24):1044-51. PubMed ID: 21920453 [TBL] [Abstract][Full Text] [Related]
12. Mechanisms of transcription factor deregulation in lymphoid cell transformation. O'Neil J; Look AT Oncogene; 2007 Oct; 26(47):6838-49. PubMed ID: 17934490 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of transcription factors with small organic molecules. Berg T Curr Opin Chem Biol; 2008 Aug; 12(4):464-71. PubMed ID: 18706517 [TBL] [Abstract][Full Text] [Related]
14. SLC transporters as therapeutic targets: emerging opportunities. Lin L; Yee SW; Kim RB; Giacomini KM Nat Rev Drug Discov; 2015 Aug; 14(8):543-60. PubMed ID: 26111766 [TBL] [Abstract][Full Text] [Related]
16. Sp1-targeted inhibition of gene transcription by WP631 in transfected lymphocytes. Mansilla S; Priebe W; Portugal J Biochemistry; 2004 Jun; 43(23):7584-92. PubMed ID: 15182200 [TBL] [Abstract][Full Text] [Related]
17. Murine models to investigate pharmacological compounds acting as ligands of PPARs in dyslipidemia and atherosclerosis. Tailleux A; Torpier G; Mezdour H; Fruchart JC; Staels B; Fiévet C Trends Pharmacol Sci; 2003 Oct; 24(10):530-4. PubMed ID: 14559405 [No Abstract] [Full Text] [Related]
18. Complex regulation of autophagy in cancer - integrated approaches to discover the networks that hold a double-edged sword. Kubisch J; Türei D; Földvári-Nagy L; Dunai ZA; Zsákai L; Varga M; Vellai T; Csermely P; Korcsmáros T Semin Cancer Biol; 2013 Aug; 23(4):252-61. PubMed ID: 23810837 [TBL] [Abstract][Full Text] [Related]
19. Molecular targets in the discovery and development of novel antimetastatic agents: current progress and future prospects. Wong MS; Sidik SM; Mahmud R; Stanslas J Clin Exp Pharmacol Physiol; 2013 May; 40(5):307-19. PubMed ID: 23534409 [TBL] [Abstract][Full Text] [Related]